Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells

Mutational status of TP53 together with expression of wild-type (wt) IGHV represents the most widely accepted biomarkers, establishing a very poor prognosis in B-cell chronic lymphocytic leukemia (B-CLL) patients. Adoptive cell therapy using allogeneic HLA-mismatched Natural killer (NK) cells has em...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Immunol
Päätekijät: Sánchez-Martínez, Diego, Lanuza, Pilar M., Gómez, Natalia, Muntasell, Aura, Cisneros, Elisa, Moraru, Manuela, Azaceta, Gemma, Anel, Alberto, Martínez-Lostao, Luis, Villalba, Martin, Palomera, Luis, Vilches, Carlos, García Marco, José A., Pardo, Julián
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2016
Aiheet:
Immunology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081347/
https://ncbi.nlm.nih.gov/pubmed/27833611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2016.00454
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia